Policy & Regulation
Definium Therapeutics reports positive Phase 3 results for DT120 in generalised anxiety disorder
12 August 2026 - Late-stage clinical biopharmaceutical company Definium Therapeutics Inc (Nasdaq:DFTX) on Wednesday reported positive topline results from its Phase 3 Voyage study evaluating DT120 (ly...
Astorg completes acquisition of Thermo Fisher Scientific's microbiology business
12 August 2026 - Private equity firm Astorg announced on Wednesday that it has completed its acquisition of the global microbiology business of life science and clinical research company Thermo Fisher...
Natera to support Phase 1 trial of Kupando's immunotherapy in advanced skin cancers
12 August 2026 - Cell-free DNA and precision medicine company Natera Inc (NASDAQ:NTRA) said on Wednesday that it will provide its Latitude tissue-free molecular residual disease (MRD) assay for a Phas...
Graviton BioScience's Investigational New Drug (IND) application for GV101 cleared for Friedreich's ataxia treatment
12 August 2026 - Graviton BioScience Corporation, a privately held, clinical-stage biotechnology company developing a diverse pipeline of therapeutics, including selective ROCK2 inhibitors for metabol...
Laekna's New Drug Application for LAE002 (afuresertib) accepted by China's NMPA
12 August 2026 - Chinese biotechnology company Laekna (HK:2105) announced on Tuesday that the New Drug Application (NDA) for LAE002 (afuresertib) has been accepted by the Center for Drug Evaluation (C...
EIT Pharma's lonafarnib New Drug Application accepted for review by US FDA for chronic hepatitis D treatment
12 August 2026 - Biotechnology company EIT Pharma Inc announced on Tuesday that the US Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for lonafarnib for the ...